Ventyx Biosciences (VTYX) to Release Earnings on Tuesday

Ventyx Biosciences (NASDAQ:VTYX) will likely be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Ventyx Biosciences to post earnings of ($0.54) per share for the quarter.

Ventyx Biosciences Stock Performance

NASDAQ:VTYX opened at $1.61 on Friday. The company has a market capitalization of $113.84 million, a PE ratio of -0.68 and a beta of 0.52. The company has a 50 day simple moving average of $2.04 and a two-hundred day simple moving average of $2.16. Ventyx Biosciences has a fifty-two week low of $1.57 and a fifty-two week high of $11.48.

Analyst Ratings Changes

Several brokerages have recently commented on VTYX. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Insider Transactions at Ventyx Biosciences

In other Ventyx Biosciences news, insider John Nuss sold 13,161 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86. Following the transaction, the insider now directly owns 485,701 shares in the company, valued at $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sheila Gujrathi purchased 130,000 shares of Ventyx Biosciences stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the transaction, the director now directly owns 130,000 shares of the company’s stock, valued at approximately $300,300. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 18.18% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.